Calls for a halt to heart stem cell trial based on controversial research

heart

Days after Harvard Medical School said it found extensive falsified or fabricated data from the laboratory of a prominent heart researcher, doctors and scientists are urging a halt to a medical trial based in part on his work. They say that sick people should not be subjected to the risks of an experiment whose underlying science has been called into question.

[Piero] Anversa is not directly involved in the heart failure trial, which is being run by a national clinical trial network supported by $63 million in federal funds. But given the turmoil and uncertainty over the work that helped lay the foundation of the trial, outside researchers called for a pause and careful examination of whether it should proceed. The trial carries inherent risks, because it requires an invasive biopsy that can cause serious complications.

One patient died after their heart was perforated during a biopsy.

“I think that the trial should be halted, and they should have an external review,” said Darryl Davis, a cardiologist at the University of Ottawa Heart Institute studying how to regenerate heart tissue. “The Anversa data comprised part of the rationale for that trial, and I think we have to understand better what these cells actually can do before we subject the patients to the risk of having an invasive procedure.”

Read full, original post: Scientists argue heart stem cell trial should be paused

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-04-23-at-11.00.36-AM
Regulators' dilemma: Thalidomide, Metformin, and the cost of getting drug approvals wrong
Picture1-5
Science Disinformation Gap: The transatlantic battle over social media and censorship
ChatGPT-Image-May-13-2026-11_56_08-AM
After slashing global health aid by $19 Billion, Trump moves to tap $2.1 billion more—to cover shutdown costs
ChatGPT-Image-May-12-2026-08_39_41-PM
GLP podcast: Big Pharma, Big Ag, Big Food—health harming industries or life-saving innovators?
Screenshot-2026-02-20-at-10.48.04-AM
Deepfakes raise profound ethical questions in science
Picture1-1
Cooling the planet with balloons: Could a geoengineering gamble slow global warming?
Screenshot-2026-05-01-at-1.29.41-PM
Viewpoint: What happens when whole grains meet modern food manufacturing? Labels don’t tell the whole story.
ChatGPT Image May 10, 2026, 08_16_59 PM 2
Overmedicalization? RFK Jr.’s antidepressant crackdown raises conflict questions over his fee stake in Wisner Baum, the tort firm built on suing drug makers
ChatGPT-Image-Apr-13-2026-02_20_22-PM
Viewpoint: Misinformation infodemic? Why assessing evidence is so challenging 
Screenshot-2026-05-12-at-9.58.31-PM
'He seems fine': Marty Makary out as FDA commissioner
S
As vaccine rejectionism spreads, measles may be taking a more dangerous turn
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.